News
NURO
4.580
0.00%
0.00
Correction to Nuro Names Mancini as CFO Article
Dow Jones · 05/19 15:59
Nuro Names Mancini as CFO Ahead of Planned Robotaxi Rollout
Dow Jones · 05/19 14:54
Nuro Reaches $6B Valuation as Series E Round Includes Uber, Nvidia
Dow Jones · 08/21/2025 17:46
Medical tech firm ElectroCore Q2 revenue beats expectations
Reuters · 08/06/2025 20:31
electroCore Inc. Reports 20% Increase in Q2 2025 Net Sales to $7.4 Million; GAAP Net Loss Widens to $3.7 Million, EPS at $0.44 Loss
Reuters · 08/06/2025 20:17
Uber, Lucid and Nuro to Launch Robotaxi
Dow Jones · 07/17/2025 12:50
More
Webull provides a variety of real-time NURO stock news. You can receive the latest news about Neurometrix Inc through multiple platforms. This information may help you make smarter investment decisions.
About NURO
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.